"10.1371_journal.pone.0025683","plos one","2011-09-30T00:00:00Z","Ana L Alessandri; Rodger Duffin; Andrew E Leitch; Christopher D Lucas; Tara A Sheldrake; David A Dorward; Nik Hirani; Vanessa Pinho; Lirlândia Pires de Sousa; Mauro M Teixeira; John F Lyons; Christopher Haslett; Adriano G Rossi","Medical Research Council Centre for Inflammation Research, The Queens Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom; Imunofarmacologia, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Astex Therapeutics, Cambridge, England, United Kingdom","Conceived and designed the experiments: ALA RD AGR. Performed the experiments: ALA RD AEL CDL TAS DAD. Analyzed the data: ALA RD CDL. Contributed reagents/materials/analysis tools: JFL. Wrote the paper: ALA RD AEL CDL CH AGR. Intellectual input into study design and manuscript editing: NH VP LPdS MMT.","The authors have read the journals policy and have the following conflict: The authors have a non-financial academic link with Astex Therapeutics who kindly gifted them with the cyclin-dependent kinase inhibitor, AT7519. This compound is also commercially available (Selleck). This does not alter the authors adherence to all PLoS ONE policies on sharing data and materials.","2011","09","Ana L Alessandri","ALA",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
